Compositions and methods for in vitro cultivation and/or expansion of regulatory T cells

Patent metadata

Field	Value
Publication number	US-11384336-B2
Application number	US-201716465773-A
Country	US
Kind code	B2
Filing date	Dec 7, 2017
Priority date	Dec 7, 2016
Publication date	Jul 12, 2022
Grant date	Jul 12, 2022

Abstract

FOXP3+ regulatory T cells (Tregs) can represent powerful adoptive immunotherapies for autoimmune diseases, metabolic diseases, and other chronic inflammatory diseases. The present invention is related to the ability to maintain and expand stable Treg lines and can provide insight into FOXP3+ Treg physiology and can enable feasible strategies of Treg-based immunotherapy.

First claim

That which is claimed:

1. An in vitro method of preparing a regulatory T-cell (Treg) population comprising:
exposing T-cells to a medium comprising an anti-inflammatory cytokine and an anti-inflammatory cytokine receptor inhibitor; and
propagating the T-cells in the medium comprising the anti-inflammatory cytokine and the anti-inflammatory cytokine receptor inhibitor to provide the Treg population, wherein the anti-inflammatory cytokine is IL-2 and the anti-inflammatory cytokine receptor inhibitor is an anti-CD25 antibody and/or a fragment thereof.

2. The in vitro method of claim 1 , further comprising, prior to the exposing step, activating the T-cells to provide activated T-cells, and wherein the exposing step comprises:
exposing the activated T-cells to the medium comprising the anti-inflammatory cytokine and the anti-inflammatory cytokine receptor inhibitor.

3. The method of claim 1 , wherein the T-cells are naïve T-cells.

4. The in vitro method of claim 2 , wherein the T-cells are activated in the presence of TGF-β and/or IFN-β.

5. The in vitro method of claim 2 , wherein the T-cells are activated in the presence of an antigen, a superantigen, and/or a mitogenic stimulus.

6. The in vitro method of claim 1 , wherein the Treg population is an antigen-specific Treg population.

7. The in vitro method of claim 1 , wherein the Treg population comprises FOXP3 + Tregs.

8. The in vitro method of claim 1 , wherein the Treg population comprises CD4 + CD25 + FOXP3 + Tregs.

9. The in vitro method of claim 1 , wherein the Treg population comprises Tregs expressing Nrp1 and/or Helios.

10. The in vitro method of claim 1 , wherein the concentration of the anti-inflammatory cytokine is in a range of about 1 pM to about 10 nM.

11. The in vitro method of claim 1 , wherein the concentration of the anti-inflammatory cytokine receptor inhibitor is in a range of about 1.0 μg/ml to about 32 μg/ml.

12. The in vitro method of claim 1 , wherein the anti-CD25 antibody and/or fragment thereof is an anti-human CD25 antibody and/or a fragment thereof.

13. The method of claim 1 , further comprising a step of administering a therapeutic amount of the Treg population to a subject in need thereof.

14. The method of claim 13 , wherein the administering elicits a tolerogenic response in the subject.

15. An in vitro method of maintaining a Treg population comprising:
maintaining the Treg population prepared according to claim 1 in the presence of the anti-inflammatory cytokine and the anti-inflammatory cytokine receptor inhibitor.

16. The in vitro method of claim 1 , wherein the anti-CD25 antibody and/or fragment thereof binds human CD25.

Assignees

• Univ East Carolina

Inventors

• Wilkinson Daniel Stephen
• Mannie Mark D

Classifications

• A61K40/416

  Antigens related to auto-immune diseases; Preparations to induce self-tolerance · CPC title

• A61K40/22

  Immunosuppressive or immunotolerising · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• C12N5/0637 Primary

  Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg · CPC title

• C12N2501/24

  Interferons [IFN] · CPC title